Wall Street hits more than two-week high on energy, tech gains

All eyes on August CPI report on Tuesday; Bristol Myers rises on FDA approval for psoriasis drug; Twitter says Musk’s latest attempt to renege deal invalid


Wall Street | Dow Jones


Energy and technology shares helped drive U.S. stocks to their highest in more than two weeks on Monday ahead of a crucial inflation reading this week that could determine the pace of interest rate hikes by the Federal Reserve.

All of the S&P 500 sectoral indexes were up in early trading, led by a 2% jump in energy shares. Oil prices rose as supply concerns mounted amidst uncertainty over Iranian nuclear talks.

Heavyweight Amazon.com, Tesla Inc and Apple Inc added between 1.2% and 2.1%, providing the biggest boost to S&P 500 and the Nasdaq.

The three major U.S. stock indexes rallied sharply last week, as investors took advantage of a sharp drop in stock prices since mid-August that was triggered by concerns over soaring inflation and the impact of tighter monetary policy to curb it.

All eyes are on consumer prices data on Tuesday for any signs that price pressures may be easing. Headline inflation is expected to rise at an 8.1% pace over the year in August, compared with 8.5% in July.

Core CPI, which strips out volatile factors such as energy and food, is expected to increase to 6.1% from 5.9% in the previous month. A recent retreat in commodity prices, especially oil, has boosted hopes that the worst of price pressures is over.

A soft number might revive speculation the Fed will only hike by 50 basis points this month, though it would likely have to be very weak to have a real impact on the hawkish stance taken by most policymakers recently.

Money markets are pricing in an 89% chance of a third straight 75 basis point increase by the U.S. central bank on Sept. 21.

“Investors expect the CPI data to show a continued decline in inflationary reading, which would be encouraging to investors, since the FOMC meeting occurs only a week later,” said Sam Stovall, chief investment strategist at CFRA Research in New York.

“Our economists are expecting a 50-basis-point hike at the September meeting though I think the chances of a 75-bps hike are equally possible.”

At 9: 51 a.m. ET, the Dow Jones Industrial Average was up 216.93 points, or 0.67%, at 32,368.64, the S&P 500 was up 34.33 points, or 0.84%, at 4,101.69, and the Nasdaq Composite was up 100.13 points, or 0.83%, at 12,212.44, their highest levels since August 26.

Also aiding sentiment, Ukrainian forces swept further across territory seized from fleeing Russian troops on Monday, as Moscow grappled with the consequences of the collapse of its occupation force in northeastern Ukraine.

“With Ukraine now putting Russia on the defense and taking over many of the territory that had been lost, that is encouraging to global investors because it implies that maybe some ceasefire will occur more quickly than earlier anticipated,” Stovall added.

Bristol-Myers Squibb Co gained 6.2% after the U.S. Food and Drug Administration approved the company’s oral treatment for adults with plaque psoriasis.

Shares of Amgen, which makes psoriasis drug Otezla, fell 3.4%.

Carvana Co jumped 11.7% as Piper Sandler upgraded the online used-car seller’s stock to “overweight” from “neutral”, saying it is grossly undervalued.

Twitter Inc slipped 1% after the social media company said it did not breach any agreement for paying a whistleblower and that Elon Musk’s attempt to terminate his $44 billion deal was invalid.

Advancing issues outnumbered decliners by a 5.21-to-1 ratio on the NYSE and by a 2.11-to-1 ratio on the Nasdaq.

The S&P index recorded three new 52-week highs and no new lows, while the Nasdaq recorded 19 new highs and 18 new lows.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor